Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 41 EP493 | DOI: 10.1530/endoabs.41.EP493

ECE2016 Eposter Presentations Diabetes complications (55 abstracts)

The influence of glycemic control on bone mineral density and bone metabolism in patients with Type 2 Diabetes Mellitus

Eleftheria Barmpa 1 , Spyros Karamagiolis 2 , Stelios Tigas 3 , Parthena Navrozidou 4 , Marianna Vlychou 4 , Ioannis Fezoulidis 4 , Georgios N Koukoulis 1 & Alexandra Bargiota 1


1Department of Endocrinology and Metabolic Diseases, University of Thessaly, Larissa, Greece; 2General Hospital of Larissa, Larissa, Greece; 3Department of Endocrinology, University of Ioannina, Ioannina, Greece; 4Department of Radiology, University of Thessaly, Larissa, Greece.

Introduction: Although patients with type 2 diabetes mellitus (T2DM) have normal or higher bone mineral density (BMD) comparing to healthy subjects, they appear to be at high risk of osteoporotic fractures. Factors that contribute to bone fragility in T2DM are not clearly understood. The aim of this study was to evaluate the influence of glycemic control on bones in T2DM.

Methods/design: We studied 40 patients with T2DM (mean age: 54.3+3.2 years, M/F: 24/16) at baseline and after 1-year follow-up (FU). We measured HbA1c, lumbar spine (LS) and femoral neck (FN) BMD by dual energy X-ray absorptiometry (DXA). Bone resorption was assessed by β-crosslaps and bone formation was assessed by serum levels of type 1 procollagen total N-terminal propeptide (TP1NP). Patients who were on thiazolidinediones and insulin treatment were excluded from the study and these with renal or chronic disease, as well. Based on the current literature BMD changes at LS more than 3% and at FN more than 6% are considered to be significant.

Results: Mean duration of DM was 6.1+1.9 years. At FU, there were no significant changes at BMI (kg/m2) (27.8+3.4 vs 27.1+3.2, P=0.09) but significant changes were observed in mean HbA1c (7.7+0.6% vs 6.8+0.3%, P=0.034). BMD (g/cm2) at LS and FN was similar at baseline and at FU (LS: 1.074±0.104 vs 1.071±0.113. P=0.067) (FN: 0.897±0.121 vs 0.893±0.111, P=0.072). At FU, TP1NP and β-crosslaps had a significant decrease in parallel with HbA1c levels (TP1NP: 46.6+5.3 vs 41.1+2.3 P=0.045 and β-crosslaps: 371.9+10.8 vs 364+6.8 P=0.047).

Conclusion: Effective management with improvement of hyperglycemia in patients with T2DM appears to have a positive contribution on bone turnover. More patients though are needed to be studied to confirm this result.

Article tools

My recent searches

No recent searches.